Location: United Kingdom
LabGenius is advancing the discovery of protein therapeutics with their machine-learning robotic platform.
Traditional drug discovery is an expensive and resource-intensive process that relies on the manual selection and testing of designs. There are far too many combinations for people to reach an accuracy level that can be accomplished by utilising AI. By applying machine learning to the process, design is becoming immensely more efficient.
LabGenius is scaling drug-discovery with their AI-powered discovery platform named EVA. Combined with public data and data supplied by LabGenius, EVA can predict more efficient therapeutic protein designs and with more accuracy for a better outcome.
The reduced time required in protein discovery when using machine learning combined with the greater precision can reduce the time and money needed when developing new drugs. This could allow new drugs to be approved faster, and developing medicines for rare diseases will be more economically feasible.
LabGenius recently announced a further $15 million in funding to continue advancing their drug discovery platform.